| P50 | author | Pieter R. Cullis | Q88255217 |
| P2093 | author name string | Yan Liu | |
| | Genc Basha | |
| | Haitang Wang | |
| | Andrew Cottle | |
| | Mina Ordobadi | |
| | Wilder R Scott | |
| P2860 | cites work | Osteocyte control of bone formation via sclerostin, a novel BMP antagonist | Q24300347 |
| | Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance | Q24318937 |
| | Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein | Q24536172 |
| | IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples | Q27333953 |
| | Progress toward in vivo use of siRNAs-II | Q28255877 |
| | Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation | Q28269067 |
| | Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis | Q28302443 |
| | Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. | Q33901933 |
| | Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms | Q34025149 |
| | Osteoporosis prevention, diagnosis, and therapy | Q34140339 |
| | Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial | Q34375398 |
| | The promise and perils of Wnt signaling through beta-catenin. | Q34647705 |
| | ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice | Q35370268 |
| | Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. | Q36234343 |
| | Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. | Q36293364 |
| | Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo | Q36315291 |
| | Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling | Q37270647 |
| | Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles | Q37489356 |
| | Developing siRNA therapies to address osteoporosis | Q38151734 |
| | Emerging therapeutic targets for osteoporosis treatment | Q38207147 |
| | Mouse embryonic fibroblasts (MEF) exhibit a similar but not identical phenotype to bone marrow stromal stem cells (BMSC). | Q38331808 |
| | Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. | Q39913293 |
| | The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. | Q42031050 |
| | The Business of RNAi Therapeutics in 2012 | Q42212141 |
| | Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats | Q42966206 |
| | Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. | Q44128390 |
| | The natural history of sclerosteosis | Q46647658 |
| | Safety and efficacy of RNAi therapy for transthyretin amyloidosis | Q46836193 |
| | Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size | Q47348224 |
| | Romosozumab in postmenopausal women with low bone mineral density. | Q50481558 |
| | Van Buchem disease: lifetime evolution of radioclinical features | Q50482303 |
| | Identification of ApoE as an autocrine/paracrine factor that stimulates neural stem cell survival via MAPK/ERK signaling pathway. | Q51887855 |
| | A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. | Q54326868 |
| | Primary mouse embryonic fibroblasts: A model of mesenchymal cartilage formation | Q57129782 |
| | The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse | Q81319561 |
| | Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones | Q84033150 |
| | Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration | Q85683734 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 9 | |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | e363 | |
| P577 | publication date | 2016-09-13 | |
| P1433 | published in | Molecular Therapy. Nucleic acids | Q27724110 |
| P1476 | title | Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo | |
| P478 | volume | 5 | |